Anti Cd 20 Ocrevus denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Ocrevus Under Step Therapy — and How to Fight It

Step therapy ("fail-first") requires patients to try and document failure of one or more specified disease-modifying therapies before UnitedHealthcare will authorize coverage of ocrelizumab (Ocrevus). UHC's step-therapy protocol for MS typically requires trial of at least one or more platform or moderate-efficacy DMTs, and documentation of inadequate efficacy, intolerance, or contraindication before a higher-efficacy anti-CD20 therapy will be approved.

This denial is among the most challengeable in MS care, for two reasons: (1) many patients have legitimate clinical reasons why earlier-line DMTs are inappropriate (prior failure, intolerance, adverse events, or an MS subtype for which earlier agents lack an FDA-approved indication); and (2) federal and many state step-therapy reform laws require insurers to grant exceptions on clinical grounds.

## Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 (employer plans) or applicable state law, you are entitled to a full-and-fair internal review. File within the deadline on your denial notice — commonly 180 days.
• External review: Under ACA §2719, step-therapy denials are subject to independent external review after a final internal adverse decision. The standard filing window is approximately four months from the final internal denial. Expedited review (72-hour decision) is available when the standard timeline creates clinical risk.
• Step-therapy exception statutes: A growing number of states have enacted step-therapy override laws requiring insurers to grant exceptions when a required prior therapy is clinically inappropriate. If your state has such a law, your neurologist's exception request carries additional legal weight. Check with a patient advocate or your state insurance commissioner for your state's protections.
• Primary progressive MS: For patients with PPMS, note that most or all of the DMTs typically required in step-therapy protocols have no FDA-approved indication for PPMS. This is one of the strongest possible grounds for a step-therapy exception — the required "step" does not have an approved use for your disease type.

## Concrete Steps and Timeline

1. Obtain UHC's step-therapy policy for MS DMTs from your denial letter or by requesting it from UHC. Note every required prior step and the criteria for documenting failure or claiming an exception. 2. Review each required prior step with your neurologist — have the neurologist assess whether it was tried and failed, is contraindicated, caused adverse effects, or lacks an FDA-approved indication for your MS subtype. 3. File the internal appeal and/or step-therapy exception request with the full documentation package below. Many plans have a formal exception request form. 4. If denied, file for external review within the four-month window. IROs apply clinical and scientific standards; step-therapy exceptions for PPMS patients or patients with documented prior-therapy failures are frequently granted.

## Documentation to Gather

• MS diagnosis, subtype, and severity: Neurologist notes, MRI reports, EDSS or functional assessment, and relapse history establishing the clinical profile.
• Prior DMT history — complete and dated: For every therapy required by UHC's step protocol, document: drug name, start date, stop date, and reason for stopping (inadequate efficacy with supporting evidence; adverse event with clinical notes; contraindication; or inapplicable indication). Include pharmacy records and chart notes.
• Evidence of prior treatment failure (if applicable): MRI showing disease progression or new lesions while on prior therapy; relapse records while on prior therapy; clinical notes documenting physician assessment of inadequate response.
• Exception basis (if not tried): For each required prior step not tried, a letter from your neurologist explaining the specific clinical reason it was not used — adverse risk, contraindication, or lack of an FDA-approved indication for your MS subtype — with reference to applicable AAN or ECTRIMS guideline support.
• Prescriber medical-necessity letter: A comprehensive letter addressing each step in UHC's protocol, documenting the basis (failure, exception, or inapplicable indication) for each, and concluding with the clinical rationale for ocrelizumab.

## Criteria-Mapping Structure

Obtain UHC's step-therapy coverage policy in full. For each required prior step:

| Required Prior Step | Status | Evidence | |---|---|---| | [Step 1 therapy class per policy] | Tried and failed / Contraindicated / Indication inapplicable | Chart note [date]; MRI [date]; pharmacy record | | [Step 2 therapy class per policy] | Tried and failed / Contraindicated / Indication inapplicable | Chart note [date]; adverse event note [date] | | Exception basis (PPMS, if applicable) | FDA indication does not cover PPMS | FDA label, neurologist letter |

A step-therapy appeal that methodically addresses every required prior step — with dated chart evidence for each — is the most persuasive form of this appeal. Vague assertions of "failure" without dates, lab results, or MRI data are the most common reason step-therapy appeals fail at internal review.